Key Insights

Highlights

Success Rate

89% trial completion (above average)

Published Results

43 trials with published results (23%)

Research Maturity

125 completed trials (66% of total)

Clinical Risk Assessment

Based on trial outcomes

Moderate Risk

Score: 30/100

Termination Rate

8.5%

16 terminated out of 189 trials

Success Rate

88.7%

+2.1% vs benchmark

Late-Stage Pipeline

28%

53 trials in Phase 3/4

Results Transparency

34%

43 of 125 completed with results

Key Signals

43 with results89% success16 terminated

Data Visualizations

Phase Distribution

109Total
Not Applicable (20)
P 1 (11)
P 2 (25)
P 3 (28)
P 4 (25)

Trial Status

Completed125
Unknown27
Terminated16
Recruiting12
Withdrawn5
Not Yet Recruiting3

Trial Success Rate

88.7%

Benchmark: 86.6%

Based on 125 completed trials

Clinical Trials (189)

Showing 20 of 20 trials
NCT07583563RecruitingPrimary

An Observational Study of Octreotide Subcutaneous Depot in Patients With Acromegaly

NCT06930625Phase 3RecruitingPrimary

A Study to Assess the Efficacy and Safety of Debio 4126 in Participants With Acromegaly Previously Treated With Somatostatin Analogs

NCT07663318Phase 1CompletedPrimary

A Phase 1 Study to Evaluate the Relative Bioavailability of Octreotide Acetate Tablets(T25) Compared to MYCAPSSA® and The Food Effect on Pharmacokinetics Of Octreotide Acetate Tablets(T25)

NCT07814651Phase 2CompletedPrimary

A Clinical Trial to Evaluate Safety, Efficacy, Pharmacokinetics, and Pharmacodynamics of Octreotide Long-acting Injection in Patients With Acromegaly

NCT07641179Phase 2RecruitingPrimary

A Study to Evaluate MAR002 for Acromegaly

NCT04076462Phase 3CompletedPrimary

A Trial to Assess Efficacy and Safety of Octreotide Subcutaneous Depot in Patients With Acromegaly

NCT07037420Phase 2TerminatedPrimary

ALXN2420 Versus Placebo in Combination With Somatostatin Analogs in Participants With Acromegaly

NCT04261712Phase 2TerminatedPrimary

A Study to Evaluate the Long-Term Safety and Efficacy of Paltusotine for the Treatment of Acromegaly (ACROBAT Advance)

NCT05131100CompletedPrimary

Korean Regulatory Post Marketing Surveillance for Somavert

NCT05192382Phase 3TerminatedPrimary

A Study to Evaluate the Safety and Efficacy of Paltusotine for the Treatment of Acromegaly (PATHFNDR-2)

NCT04837040Phase 3TerminatedPrimary

A Study to Evaluate the Safety and Efficacy of Paltusotine for the Treatment of Acromegaly

NCT07659912Not Yet RecruitingPrimary

Direct Versus Video Laryngoscopy in Patients With Acromegaly

NCT04349839CompletedPrimary

ACRODAT Prospective Evaluation Study

NCT00461188RecruitingPrimary

Genetics of Endocrine Tumours - Familial Isolated Pituitary Adenoma - FIPA

NCT00921609CompletedPrimary

Peri-operative Dynamics of the Growth Hormone Axis in Subjects With Acromegaly

NCT07195175Phase 1RecruitingPrimary

Study of MAR002 in Healthy Men

NCT04125836Phase 3CompletedPrimary

A Trial to Assess the Long-term Safety of Octreotide Subcutaneous Depot in Patients With Acromegaly

NCT04066569Not ApplicableCompletedPrimary

Reproducibility and Utility of OGTT in Acromegaly

NCT05364944Phase 1TerminatedPrimary

A Study to Assess the Pharmacokinetics, Pharmacodynamics, Safety, and Tolerability of Debio 4126 in Participants With Acromegaly or Functioning Gastroenteropancreatic Neuroendocrine Tumors (GEP-NETs)

NCT07179926Recruiting

Effects of Pasireotide Lar Therapy on Bone Metabolism

Scroll to load more

Research Network

Activity Timeline